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Abstract 
o teoarthriti i a di ea e that attack human bone e pecial ly in older people and u ual ly noo-
teroidal anti-inflammatory drug ( I D ) are being pre cribed for patient with 
teoarthri ti . The e kind of drug usually have low aqueou olubi l i ty and in  order to ba e 
their therapeutic effect , their olubi l i ty hould be enhanced. The purpo e of thi study was to 
find olution for thi prob lem and one way to do that is  to reduce the part ic le ize by forming 
micropart icles .  I n  thi project, one of these types of drug ibuprofen ( isobutyl-propanoic­
phenol ic Acid) was encapsulated into a polymer ( PVP  polyvinylpyrrol idone) u i ng 
upercri t ical fluid technology ( Supercrit ical CO� ) to fOiTIl drug-polymer micropal1icle . 
Another aim was to measure the solub i l i ty, di olution rate and surface characteristics of the 
prepared drug-polymer micropart icle by characterizing them using various characterization 
techniques uch as fourier tran foml infrared spectroscopy (FT I R),  u l traviolet spectroscopy 
(UV) ,  transmission e lectron micro copy (TEM), scanning electron microscope ( SEM), 
thermogra imetric analysi (TGA) and different ia l  scanning calorimetry ( DSC) .  Various drug­
polymer formulation were prepared depending on variou administrative dosages. D ifferent 
condi tions ( i .e .  d ifferent temperatures, pressures, flow rates and different drug solution :C02 
volume ratio) were tested in preparing drug-polymer micropart icles .  Results from TEM images 
and FT - I R  graph show that micropart ic les were successful ly  prepared. D ifferent condi tions 
gave different shape of drug-polymer micropart ic les in  the SEM results . Final ly di ssolution 
rate of the drug-polymer micropart ic les i n  the simulated gastric fluid showed promising results . 
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SO°C 1 20 bar ,  4% volume ratio, 1 ml/min  flow rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 3 
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Chapter I: Introduction 
1 . 1 .  0 teoarthriti di ea e: 
Bone di ea e are comm n e pecia l ly nowaday due to the rhythm of today' l i fe tyle, the long 
\ orkmg hour relat ive to resting hour and type of food \ e con ume. 0 teoarthriti (OA) i a 
well-known di ea e, \ hich come a a con equent of aging proces and i s  regarded a one of 
the mo t common disea e among human . Thi mu cu loskeletal di order has not only been 
de cribed in mammal of many age , but a l  0 i t  goes back to the Egyptian mummies and in the 
dino aur' era, it e act et iology i far from being ful ly  understood . As the world population i 
growing, i t  I of the utmo t importance to find out more about the pathogenesis of the di ease 
and thu al low the discovery of new treahnents to top or prevent i ts progression . 
Osteoarthri t i  i al 0 the mo t common foml of arthri t i s ;  i t  i affecting mi l l ions of people a l l  
over the world. I t  i a complex di ea e who e etiology bridges biomechanics and biochemistry . 
I t  ha been proven that systemic factor ( uch as genet ics ,  dietary intake, e trogen use, and 
bone density) and local biomechanical factors ( uch as musc le weakness,  obesi ty and joint 
laxi ty)  are cause of this d isea e. Evidence i s  growing for the role of these two factors and 
modifying them has l ightened the road for prevention of osteoarthri t i  -related pain and 
disab i l i ty .  Major ad ance in management to reduce pain and disab i l i ty are yielding ful l  array 
of avai lable treatments ranging from nutri ceuticals to chondrocyte transplantation, new oral 
anti - inflammatory medications and health education ( 1 ) . 
Mechanical and biochemical factors are combined and global ly observed in  OA (2) .  The 
disea e process affects not only the cart i lage, but a lso the entire joint structure including the 
synovia l  membrane, subchondral bone, l igaments, and perial1 icular muscles. There are some 
changes in OA synovium, the inflammatory happens as synovial hypertrophy and hyperplasia 
wi th an i ncrea ed number of l ining cel ls, and a lso an infil tration of the sub l in ing t issue with a 
mixed population of inflammatory ce l ls .  In  patients wi th severe disease, the extent of 
inflammation can sometimes reach that observed in rheumatoid arthrit i s  ( RA)  patients at the 
c l inical stage ( 3 ) . Synovial inflammation is c learly reflected in many of the signs and 
symptoms of OA, including joint swel l ing and effusion, st iffness, and sometimes redness . 
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The mam objecti e In the management of OA are to reduce the ymptom , minimize 
functIOnal di abi iJty ,  and limit progre ion of the tructural change . cienti t ha\'e been 
earching and tried to und r tand the role of catabolic factor in carti lage degradation and the 
impli ation f nO\ ial inflammation in the l ast two decade (4) .  These finding ha e made 
po Ib le more preci e identi fication of pathway that have the potential to become therapeutic 
target . 
linical tudi to date have focu ed on the a l Je iation of signs and ymptom of mi ld-to­
moderate OA ca e using nonsteroidal anti-inflammatory drugs ( SAI Ds)  ( 5 ) .  Published data 
on intraarticular corti co teroids in OA ha e demon trated short-tenn (up to 4 weeks) 
improvement of ign and symptom compared with placebo (6). 
1 .2.  'on teroidal Anti-Inflammator Drugs (NSAID's): 
on-steroidal anti-inflammatory dll gS are usual ly abbreviated to SA ID  or NALDs, but also 
referred to a non teroidal anti -inflammatory agent /analgesics (NSAIAs) or nonsteroidal anti­
inflammatory medicines (NSAIMs) .  They are drugs with analge ic and antipyretic ( fever­
reducing) effect , which have in higher dose anti-inflammatory effects ( 7) ,  analgesic, and 
antipyretic effect and inhibit  thrombocyte aggregation. The drugs have no documented effect 
on the disease process it elf (8 ) .  
A survey conducted for the World H ea l th Organization (WHO)  reported that one adul t  in five 
uffer from chronic non-malignant pain,  which mostly occurs in the back, head, joints and 
limb . More than 1 5% of the worldwide population suffers from some fonn of osteoarthri tis, 
and this  incidence is  even higher in e lderly people .  As the world population is  growing older, 
this  incidence wi l l  continue to rise (9 ) .  onsteroidal anti -inflammatory drugs (NSA I Ds)  have 
become one of the most commonly u ed medications in Western nations since the introduction 
of the first SA ID  and a pirin about one century ago. I t  is estimated that more than 70 mil lion 
SA ID  prescriptions and more than 30 bi l lion of over-the-counter aspirin, ibuprofen 
ketoprofen, and naproxen preparations are sold annual ly in the Uni ted States alone. Although 
SAIDs  are general ly well  tolerated; their use frequently is limited by adverse gastrointestinal 
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effect rangl llg from dy pep ia  to enou complication , uch a wel l ing bleeding or 
perforat Ion from ga tri c  or duodenal ulcer ( 1 0) .  
1 .2 . 1 .  olubi l ity of I D  
common l imitat Ion with 10 i the ir  olubi l i ty .  According to the e tab l i  hed tati t ic , 
about a third of th drug I i  ted in the United State Pham1acopeia are poorly water- oluble or 
in oluble and more than 40�'o of new drug development ha fai led because of poor 
blOpharmaceutical prop rtie . Yariou technique have been deve loped to address the olubi l i ty 
i ue, inc luding micronization, urfactant-aid di persion, the use of organic solvents emulsion 
and microemul ion ol id di per ion technology and carrier based on polymers and 
l ipo orne ( 1 1 - 1 6) .  
The earch continues  for more e ffect ive and versat i le techniques  appl icable to the formulation 
of drugs with d ifficul ty in  aqueou solubi l i ty .  The nanosizing of drug partic les has been 
identified a a potent ia l ly effect ive and broadly appl icable approach, with impl ications beyond 
the mi tigation for water insolubi l i ty .  For example, smal ler-diameter part ic les correspond to a 
faster d is  olut ion rate, thu potent ia l ly h igher activ ity and easier absorption. Other di tinct 
advantage of nano izing of the drug partic les inc lude tissue or ce l l  specific  targeting of drugs 
longer c i rculating capaci ty in the b lood, h igher stabi l i ty against enzymatic degradation, and the 
reduction of unwanted side effects ( 1 7-20) .  
l .2 . 2 .  Types of SAIDs  
SAIDs can be classified based on the i r  chemical  structme or  mechanism of action. Earl ier 
types of TSA I Ds were known long before their  mechanism of action was discovered and were 
for this rea on c lassified by chemical structure or origin .  Newer substances are more often 
c1as i fied by mechanism of action. For example sal icy lates (e .g.  Aspi ri n  ( acetylsal icyl ic acid)), 
propionic acid derivative (e .g .  Ibuprofen) ,  acet ic acid derivatives (e .g. Dic lofenac, enol ic acid 
( Oxicam) derivatives (e .g .  P i roxicam), fenamic acid derivatives ( Fenamates ) (e.g. Mefenamic 
acid ), se lective COX-2 inhibi tors (Coxibs) (e .g .  Parecoxib) and sulphonanil ides (e .g. 
imesul ide )  have a l i t t le d ifference in  c l in ical e fficacy when used at equivalent doses, and the 
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difference among compound tend to be within the range of do ing regimen (re lated to the 
c mpound' e l imination hal f- l i fe ), route of admini tration and tolerabi lIty profile .  
]n th l  \i ork ibuprofen, which ha the 1 P C nomenclature of 2-(p-i obutylphenyl )propanoic 
a id \Va u ed a a mode l  non teroidal anti - inflammatory drug . Ibuprofen is  u ed for re l ief of 
ymptom of ar1bri t i  , fe er ( 2 1 )  and al 0 a an analgesic agent for pain, e pecia l ly where there 
i an in f lammatory component .  Ibuprofen ha the fol lowing chemical structure :  
Ibuprofen i a core medicine i n  the World Health Organization' "WHO Mode l  List of 
E ential Medicine ", which i a Ii t of minimum medical needs for a basic healthcare sy tern 
(22) .  Ibuprofen is al 0 being u ed primari ly for fever inflammatory diseases uch as 
rheumatoid arthriti . It work by inhibi ting the enzyme cyclooxygena e (COX), which converts 
arachidonic acid to prostaglandin H :!  ( PGH2)  which in turn, is converted by other enzymes to 
everal other pro tag landins ( which are mediator of pain inflammation and fever) (23 ). 
Ibuprofen wa derived from propionic acid by the re earch team of Boots Group during the 
1 960 (24) .  It a disco ered by Andrew RM Dunlop and his col leagues and the drug was 
launched a a treatment for rheumatoid arthri t i s  in the Uni ted Kingdom in 1 969, and in the 
Uni ted States i n  1 974. 
1 .3 .  Biodegradable Polymers 
The use of polymer-based drug de l ivery systems in  medical therapies i s  of growing interest .  
Synthet ic b iodegradable polymers that can be appl ied without causing undesirable effects to 
l iv ing sy terns (in vivo) are now popular choices to e l iminate problems with some drugs that 
have a narrow therapeut ic range . B iodegradable polymers are commonly used as materials for 
drug de l ivery systems because the i r  permeab i l i ty and diffusiv ity can be modified and 
contro l led.  They can be shaped eas i ly  by a large variety of proces  ing methods. B iodegradable 
polymers are used in suture, medical treatment of bone fractures and more recently as carriers 
of drugs in con trol led-re lease preparations (25-26) .  B iodegradable polymers have offered 
scientists a possib le solution to waste-disposal problems associated with tradi tional petroleum­
deri ed plastics (26) .  B iodegradation is defined as an event which takes place through the 
action of enzymes  and/or chemical decomposi t ion associated with l iv ing organi sms (bacteria,  
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fungi, etc . )  and their  ecret ion product (27). I t  i al 0 nece ary to con ider biotic reaction 
l ike photodegradation, oxidation and hydroly i s  which may al 0 al ter the pol m r before, 
dunng or in tead of biod gradation becau e of en ironmental factor . 
BIOdegradable polymer can be u ed a control led drug de l ivery systems of bioactive agent 
and drug . They can be u ed for thi purpose in  form of fi lms, ponge , microspheres and 
nanopart i Ie . H owever, the mo t intere ting route eem to be the use of micro and 
nanoparticJe . mong biodegradable polymer , natural polymers promi e better drug de l ivery 
efficienc , a  reduced toxic ity and an impro ement of patient compl iance (28) .  Control led drug 
de l ivery product , using biocompat ible or biodegradable polymers ha e received considerable 
attention in the pa t year . The e ubstance prov ide in  general a more control led rate of 
di olut ion of the drug in ide the body which w i l l  improve its therapeutic action. In fact there 
i a growing intere t of the phamlaceutical industry in  the deve lopment of these system (29) .  
1 .3 . 1 .  Phy ica1 properties of polymers in  supercri t ical CO2 
Polymer are usual ly swol len  in a supercri t ical atmosphere due to the interactions between 
polymer and upercrit ical CO� . Fourier Transform Infrared ( FTI R)  and A TR IR  spectroscopy 
are u ed to study the spec ific intermolecular i nteract ions between supercri t ical CO2 and the 
polymers (30) .  Polymers usua l ly consist of long chains whi le ol igomers are made of short ones 
which wi l l  affect the chain flex ib i l i ty .  The chain f lexibi l i ty of polymers can aid dissolution in  
supercri t ical CO�, carbonyl or e ther group tbat are accessible in  the backbone or  on side 
chains can pecifica l ly  interact with supercri tical CO2 (e .g. PLA) .  Also polymers with ether 
group (e .g.  polyethylene glycol ( PEG ) showed stronger interaction than polyesters due to 
weak Lewis  acid-ba e interact ion i n  polyesters ( 3 1 ) . 
1 .3 .2 .  Solubi l i ty of CO� i n  polymers 
Molecular structure ( the interact ion between CO2 and molecular cbains) and tbe morphology 
(crystal l i ne or amorphous, re lated wi th free volume )  of polymers wi l l  influence CO2 solubi l i ty 
and d iffusivity. The solubi l i ty of CO2 in  many polymers (e .g. poly methyl methacrylate 
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( PV1 ) and poly- tyrene ( P  )) ,  ha been tudied by evaluating CO2 sorption and polymer 
" e J l l l1g ( 36-3 . There wa a general perception that orption and wel l ing i a purely phy ical 
phenomen n until Fourier tran fonn-infrared ( FTI R) and ATR l R  pectroscopy were u ed to 
tudy the pecIfic intemlolecular interaction between CO2 and polymers (39-4 1 ). 
Al though poly( lactlc acid) ( PL ) and poly ( lactic acid-co-glycol ic ac id) ( PLGA) have the 
arne chemical tructure in the main chain , the teric hindrance clo e to the carbonyl group 
and acce lb le free volume cau ed by methyl pendant group can lead to their different 
beha ior of olubi lj ty and interaction. In the ca e of PLGAs, ome methyl group are 
ub tl tuted with hydrogen atom which cau e much Ie  hindrance for the interaction with the 
upercri t ical CO2. However, the acce ible polymers free olume was found to have a greater 
effect on olubi l i ty than the interact ion between polymer and CO2 (32) .  Therefore, the 
olubi l i ty of CO2 in PLGA copolymer decrease with the increase in the glycol ic acid content .  
l .3 . 3  Polymer uti l ized in  thi  re earch 
Poly\ i nylpyrrol idone ( PVP) ,  which is a water-soluble polymer was used in this study. PVP is 
also cal led poly idone and i t  has the fol lowing chemical structure : 
One of the a l ient features of PVP i s  i ts universal solubi l i ty which extends from the extremely 
hydrophi l ic solvents such as water to hydrophobic l iquids such as butanol . Today the use of 
organic sol ents such as methylene ch loride or ch lorofom1 i s  severely restricted, but 
nevertheless smal l  quant i t ies of organic solvents are sti l l  used by most pharmaceutical 
compani es .  Polyvinylpyrrol idone has been used in  phannaceutlcals such as ointments, 
dis infectant , surgical scrubs or as a b inder in many pharmaceutical tablets (42) and it simply 
passes through the body when taken oral ly .  
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1 .4. Micro neap ulation methodologie 
The main purpo e of mlcronizing drug/polymer y tem i to enban e the drug del ivery. 
Control led drug del i\'ery occur when a pol mer/drug y tern i de igned to relea e the drug in 
a predetermined manner a bown in F igure 1 .  In other word , control led release y tem are 
u ed to ach ieve a more effective therapy, i . e . ,  a y tem witb a del ivery profile that would yield 
a high drug Je e l  in the blo d o er a long per iod of time, avoiding the large fluctuations in drug 
concentration and to r duce the need of everal administration (52 ) . I n  many case , 
con entional drug del ivery product pro ide harp increa es in the drug concentration at 
potent ialt toxic I el , folio ed by a relatively short per iod at the therapeutic level and drug 
concentration drop unti l new ad mini  tration a hown in Figure 1 a  ( 53 ) .  
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Figure 1 .  D rug levels in  the blood with (a )  tradi tional drug dos ing and (b)  control led-del ivery 
dosing 
Micro- and nanopartic les composed of a biologically active compound, and a biodegradable 
polymer acti ng as a carrier , represent one of the most studied systems in the research for new 
drug del ivery systems ( 54) .  In such formulations, the polymer enhances the phalmacological 
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feature f the drug uch a ol ubi l ity in the ga tr ic fluid and tabi l i ty .  Depending on the 
degradation rate of the bio ompatible polymer the polymer al 0 enhance the control led 
relea e of the drug hence r ducing the number of required do e ( 5 5 )  a hown at Figure 1 b .  
1 .4. 1 .  onventional microen ap ulation method 
everal traditional  part ic le ize r duction or microencap ulation technique such as mechanical 
mi l l ing, ernul ion and precipitati n-condensation method have found orne ucces in the 
preparing drug nanopart ic le , but i ues including the broad part ic le size di tr ibution in 
product and the e ce j e use of organic 01 ent remain to be addressed. 
1 .4 .2 .  upercr i t ical F luid Techno logy 
I ntere t in supercr i tical fluid (SCF ) and their potential use for process improvements has 
ignificantly increa ed in the pa t decade. Propert ies of the e fluid can be tuned by changing 
the fluid dens i ty between those of l iquid and gases .  SCFs have been adopted as: (a) a l ternative 
o l\'ent for c Ia  ical eparation processes such as extraction, fractionation, adsorption, 
chromatography. and cry ta l l i zation, (b) a reaction media as in  polymer ization or 
depolymer ization, or ( c )  simply as reprocessing fluid as in  production of part ic les, fibres or 
foam . Part ic le fonnation w i l l  most l i kely be the second major commercial  appl ication area 
that uses upercri ti ca l  fluids after the extraction ( 50) .  Carbon Dioxide (C02) is the most 
commonly used fluid in supercr i t ical fluid technologies. 
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Figure 2. Pha e diagram of upercr i t ical CO2 
ome of the ad antage of supercr i t ical CO2 are i ts mi ld operation condition (cr i tical 
t mperature and pre ure of 3 1 °C and 7 .38M Pa, respectiv Iy)  Figure 2 gaseou standard state 
under ambient condit ions, nontoxic i ty and i t' s  relatively low co t compared to organic 
olvents. The favourable physical and chemical properties of CO:?, are some of the reasons why 
o many application that u e supercr i t ical CO2 focu on pharmaceuticals and biological 
mater ia ls  ( 5 1 ) . Supercr i t ical CO2 ha special  propert ies which makes i t  an excellent 
environment for the fonnation of dry part icles, such as ibuprofen, aceclofenac, diclofenac and 
other SAID . One of these propert ies is the low solubi l i ty of most drug molecules in 
upercr it ical CO2 which is con idered as an advantage as well  as a chal lenge. 
upercr it ical fluid processing techniques have been appl ied to the part ic le fom1ation in drug 
formulation (43-48) .  The methods of fine part ic le fom1ation using supercr it ical CO2 are 
c la ified into se eral categor ies according to the role of supercr i t ical C02 and the use of the 
second solvent. These include supercr i ti ca l  antisolvent ( SAS), rapid expansion of supercr i tical 
solutions (RESS), and part ic les from gas-saturated solutions ( PGSS) .  A significant 
disadvantage wi th nanoscale drug par ticles is the dif ficulty in their production. The physical 
in tabi l i ty of nanoscale part ic les to undergo aggregation is also a problem in the drug storage 
and administrat ion ( 1 9-20) .  
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1 .4 .2 . 1 .  upercritlcal anti 01 ent proce ( 
upercri t l  al anti olvent micronizatJOn ha different acron m , but the proce e ential ly 
the arne In all ca e ; the d ifference are mainly related to the feed mode of olvent and 
anti ohent, being in  CO-CUlTent or countercurren t mode and to the kind of injector u ed. 
anopart ic les are produced b droplet formation and the sub equent el imination of the solvent 
due to the fa t rna tran fer of O2 in the l iquid. AS proce ha been widely appl ied in 
man field of re earch including phalmaceutical , uperconductors, coloring matter , 
explo iv , polymer and biopol mer . Th i technique i also known as the aerosol olvent 
ex traction y tem ( E )  or precipitation with a compre sed anti solvent ( PCA) process. A 
typical chematic diagram of SA process) hown at Figure 3 .  Supercri tical CO2 is a 
relatively poor 01 ent for most polymer and phannaceutical compounds. Co-solvents can be 
u ed to increa e olubi l i ty of chemical compounds in CO2. The microniza60n of polymers and 
biopolymer has been regarded a one of the earl iest appl ications of the supercritical 
anti olvent teclmique. M icronization can be perfomled in batch or semi-continuous mode. 
Al though the principle of the precipi tation process is the same, batch and semi-continuous 
proces e can produce total ly d ifferent results in  terms of morphology and particle s ize 
di tribution of the proce ed material ( 58-59) .  D ifferent paliicle morphologies have been 
produced such as nanometric and micrometrlc part ic les, amorphous part icles or crystals. 
Review can be found in the l i terature that col lec t  and comment on the results presented by the 
various authors (60) .  
The result ing part ic les are u ual ly c lose to the spherical shape, s ince this shape i s  imposed on 
the droplets by the act ion of the surface tension, and i t  is  maintained by the solid material that 
nucleate and grows within the boundaries of the original droplet .  The diameter of the injector 
influence the distribution size of the droplets and, thus, the diameter of the part ic les ( 56) .  The 
majority of the supercri t ical  anti-solvent studies have focussed on encapsulation of 
pharmaceuticals into b iodegradable poly (esters) such as PLA and PLGA (57 ) .  
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In  thl '" ork upercri t ical anti oh'
ent 
method, a u ed for the microencap ulation of ibuprofen 
into pol ' inyl pyrrol id ne. The produced micropart icle were characterized u ing different 
analytIcal method . 
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Figure 3. Schematic diagram of the SAS process 
1 .4 .2 .2 .  Solution enhanced di spersion by supercri t ical f lu ids ( SEDS)  
Th i  proces IS  a modified verSIOn of the SAS process in which the l iquid solution and 
upercrit ical fluid are sprayed together using a spec ia l ly designed coaxia l  nozzle. Two channel 
and three-channel nozzle are used for the precipi tation of s ingle and binary compounds, 
respecti e ly .  Supercri t ical fluid has a d ifferen t  role; it is used both as an anti solvent and as a 
d i  per ion medium. A h igh speed stream of solution carrying polymer, drug or any part icle 
pontaneously contacts with the supercrit ical fluid .  This generates the finely dispersed mixture 
and promptly achie es the target of part ic le precipi tation. Adoption of three processing media, 
uch as two d ifferent supercri t ical fluids and one organic solvent, can create more versati le 
operating variables. A typical schematic diagram of the SEDS process i s  shown in Figure 4 .  
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Figure 4. chematic  diagram of the SEDS 
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1 .4 .2 .3. Rapid e pansion of upercri t ical olutions ( RESS)  
Th i  proce i u ed  when the polymer has  orne degree of solub i l i ty in supercri t ical fluids. A 
typical chematic diagram of the RE S process i s  shown in  Figure 5 .  The pure drugs or drug­
pol mer mixture are d is  olved i n  a supercri t ica l  fluid and this h igh-pressure solution i s  rapidly 
depressurized thr ough an orifice to lead to part ic le prec ipi tation at a low pressure. Difference in 
solute olub i l i t ies in supercri tical  fluid at high and low pressure is  the basic idea in this process. 
HO\: ever, the main l imit ing factor is the low olubi l i ty of mo t pharmaceutical compounds and 
regulatory approved polymer in  supercri t ical CO2. To overcome this obstacle, co-solvents 
have been u ed to modify the polarity of the extracting phase and thus enhance solute solubi l i ty 
in  the supercri tical  phase. Tom and Debenedetti (6 1 )  demonstrated that when 1 % (w/w) 
acetone was used as a co-solvent, the solubi l i ty of PLLA increased by approx imately 500%. 
Gas vent 
r nozzle 
Autadave Spray chamber 
eollecta:ln 
Figure 5. Schematic diagram of the RESS process 
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1 .4 .2 .4 .  Ga anti 01 ent proce (GA ) 
Th i proce i u ed for the ol id compound that are not oluble in upercritical fluid. The 
technique i e p cia II u i table for drug-polymer mi ture becau e the majori ty of polymer 
are not oluble in upercri t ical f l uid or gase . The drug-polymer mix tures are first di olved in 
a l iquid organic 01 ent, and a gas i employed a an anti olvent for the drug-polymer mixture 
b inj ct ing ga into the olution in a c losed chamber, re u l ting in precipitation of the olid 
part ic le . In  this proce there i direct proport ional i ty between the gas concentration in 
o lution and the pres ure. U ual ly SA S needs h igher pressure than GA S (39) .  A typical 
chematic diagram of the GA proce hown in Figure 6 .  
Solvent Saturate<! solubon vent -,;;. � . ... 1 
noule 
Mixing 
Chamber 
Spray ch amber 
Powder $olven 
Fittr"atlon 
.. 
SupercriticaJ • 
Fluid 
Figure 6. Schematic diagram of the GA S proces 
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1 .4 .2 . 5 .  Part ic le from ga - aturated olution ( PG 
Thi proce i de igned for making part ic le of material that absorb supercri tical fluid at 
h igh concentration w1t i l  they get aturated. E en though the running indu trial appl ication 
rna currently be mo tl on non-polymeric material , the technique ha great promi e and i 
highly U i table for polymer powder production, particularly for powder coating appl ications. A 
typical chematic diagram of th PGS proce hown in F igure 7 .  
Fine lmctc .... 
G. 
Figu re 7. Schematic diagram of the PGSS process 
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1 .4 .3 . Formation of pol mer part ic le containing active ingredient u mg upercri tical fluid 
technology 
upercnt lcal fluId techniqu have been widely used to produce a large variety of 
pharmaceut ical compound , and micropart icle a hown in Table . l .  The prepared 
microparticle were produc d with control led part ic le ize and part ic le ize di tribution ( PSD) .  
Microparti I e  of non teroidal ant i  inflammatory drug ( A I D's )  uch a ibuprofen (63 ), 
terbulaJ ine ( 64),  u lfameth izole (45) and in ul in (46) are common products using upercri tical 
flUId technology (62) .  
In the  cia ica l  method of micropart ic le f0n11ation, when the supercri tical condition of CO2 
(pre ure and temperature) are achie ed, the l iquid solution containing the drug and the 
poJ mer i pumped to the precipi tator ves el and sprayed inside the vessel by means of a 
nozzle. Th smal l  drops of the olvent are di ssolved by supercri tical CO2, causing 
upersaturation of the l iquid olution. The consequent precipitation of the drug/polymer 
powder are formed and are accumulated on the frit located at the bottom of the vessel ,  a well 
as being deposited on the internal wal l  of the vessel .  The precipi tation process finishes when 
the desired amount of l iquid solution has been fed into the ystem, then the l iquid pump is 
turned off and the supercrit ical CO2 continue to flow through the precipitator vessel to remove 
the res idual content of the l iquid solvent olub i l i zed into the supercri t ical antisolvent (65 ) .  
I t  wa found that higher polymer to drug ratios produced higher encapsulation effic iencies and 
the coated drug particles showed sustained release behavior ( 66) .  
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Table  J .  L l terature re iew of different upercri t ical condit ion u ed in  microparticle 
formation 
Author P T Drug Polymer Solution Flo\.\ rate SpecificatIOn 
( bar) « \  ) oluti  n ( mg ml)  volume to CO� ( m l/mln)  
(mg ml)  \ ol ume ratio 
A. Tenono et al. 1 50 40 5 1 %  I 1 5 : 1 flow rate ratio 
( 2007 )  ( 1 9) 20 C02: 01.  
Vega- 1 1 0 40 prec ipitat ion 2 . 8  wto o. 60. o 6 
GonL 'alez. A. e of polymer PLA in 
al.  2004 ( 20) Only DCM* 
Yulu Wang. et 82 32 1 6  4 3 0. 0.  0.7 The maller the PS 
a!. (2004) ( 2 1 )  the more amount of 
polymer we have to 
u e. 
Jo hua R. Bush. I n  40 0.0287g 0. 1 028g 1 00. 0. 0.5 
(2007) ( 2 2 )  drug/g 
polymer 
Ana Rlta C. 80 3 5  l .2g i n  2 g  3 .2% I 
Duarte. 2006 20ml 
( 69)  ethanol 
E lisa E l izondo, 1 00 3 5  - 1 00 50.· '0. 2 -Volume of C02 
20 1 0  ( 70) 30ml. 
-Spraying angle 60 
Yulu Wang, 89.6 3 3  5 5 1 . 5 standard 0 . 8  
_006 ( 66) l iter/min SC 
CO2 
A mol  1. Thote, 1 03 .42 40 1 0  80 50.·0. I 
Ram B .  Gupta. 
2005 ( 70 )  
M .A .  T a \  ares 1 30 SO 5 7  - - - M icronization is 
Cardo 0, 2008 the object ive 
( 7 1 ) 
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1 .5 .  The i objective 
o teoarthri t J  j a common di ea e affecting many people worldwide. Pain in the joints i the 
mo t common mptom of patient uffering from osteoarthriti s .  Ibuprofen, a non teroidal 
anti - inflammatory drug, i u ual ly u ed as a pain k i l ler for 0 teoarthri t is patient . However low 
olub i l i ty of ibuprofen in the ga tric fluid is a major l imitation that affects the effecacy of thi 
drug. Therefore, the main objecti e of thi tudy wa to enhance the aquous solub i l i ty of 
ibuprofen by fOlTI1 ing drug-polymer microparticles .  Supercri tical fluid technology 
( upercri t i  al CO:J \ a u ed for encapsulating the ibuprofen drug into the 
pol yinylp n·ol idone ( P  P) polymer. In part icular, it was of our interest to use the supercritical 
anti olvent proce (SAS)  to fOlTI1 microcap ules. Different conditions ( i .e .  pressure, 
temperature, flow rate , and d ifferent drug 0lution:C02 volume rat ios) were used in the 
preparation of the drug-polymer micropart ic les, and the solubi l i ty, dis olution rate and swface 
characterist ic of the prepared drug-polymer micropaliic les were measured. Characterization 
technique included fomier transfonn infrared spectroscopy ( FTI R), u l traviolet spectroscopy 
( U  ) , tran mission electron microscopy (TEM) ,  scanning electron microscope ( SEM), 
them10gravimetric analy i (TGA) and differential  scalming calorimetry ( DSC). 
1 .6. Outl ine  of ch apters 
Chapter 2 di cusse the experimental materia ls  and methods used in this work including the 
experimental procedure, detai l of the apparatus, operating conditions used in  preparing the 
microcapsules and the characterization methods . Chapter 3 includes the results and discussions. 
Results of the characterization methods are presented, analyzed and discussed. Final ly, the 
conclusions are included in Chapter 4. 
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hapter I I. laterial and method 
2. 1 .  Material 
The nOll- teroidal anti- inflammatory drug AI D), used in tbi work wa ibuprofen odium 
alt of 9 1 .0% minImum puri ty, which wa purcha ed from igma-Aldrich Cbemical. Ethanol 
(99 .7° 0 puri ty) and dich loromethane (99.7° 0 puri ty) were uppl ied by VWR International Ltd , 
England. thanol \ ith a pUli ty of 99.9% wa uppl ied by Riedel-de Haen, Gem1any. CO� 
with puri ty higher than 99. �o wa upphed by harjah Oxygen Co. Poly inylpyrrol idone 
pol mer l,vith a molecular weight of 24,500 was generously suppl ied by the Chemi try 
Departm nt at UAE Uni er i ty. 
2.2.  Method 
2 .2 . 1 .  Fom1ation of the micropart ic les 
In the upercrit ical  anti-solvent ( SAS)  process ( Figure 8 and 9)  the experiments began by 
del ivering supercri t ical CO2 at a constant flow rate to the precipitation chamber unti l  the 
de ired supercri t ical  condi t ion (pressure and temperature) of CO2 were achieved. The l iquid 
organic olution contain ing the drug and polymer was pumped to the precipi tation vessel and 
prayed inside the ve sel by means of nozzle (ei ther 0 .075 micrometers or 0 . 1 5  micrometers 
diameters ize) .  Precip i tation of the solute was obtained and, when a given quanti ty of the 
solution was i njected, the l iquid pump was stopped. However, supercritical CO2 continued to 
flow i n  order to wash the chamber, e l iminating the organic l iquid from the precipitate. At the 
end of the washing step CO2 flow was stopped, the prec ipitation chamber was depressurized 
down to atmospheric pre ure and the sample was col lected for analysis. After each run the 
l ines were flushed wi th about 70 ml ethanol fol lowed by 1 00 ml SC CO2. Tbe experimental 
condit ions studied in this work are l i sted in Table 2 .  
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Run 
# 
1 
2 
3 
4 
5 
6 
7 
8 
9 
1 0  
I I  
1 2  
1 3  
1 4  
J 5 
1 6  
1 7  
1 8  
1 9  
20 
2 1  
22 
23 
24 
25 
Table 2. Experimental condi t Ion for ibuprofe P P rnicropart icle formation 
I buprofe p"p (g ) Solvent Temp. Pre Volume SolutJon Observation 
n (g)  vol ume (C) (bar) ratio (0 0) flo\\ rate 
( m ! )  ( m l  ml ) 
0 . 500 0. 1 25 25 40 1 50 I 1 �'\o product 
0. 507 0. 1 25 25 40 1 50 3 I A lot of product.  
0.5 0. 1 25 25 40 1 50 4 1 A lot of product.  
0.5 O. I 25 25 40 1 50 2 I A lot of product 
0.5 0. 1 25 25 40 1 20 4 I A lot of product 
0.5 0. 1 25 25 40 1 00 4 I A lot of product 
0.5 0. 1 2 5 25 40 90 4 I A lot of product 
0.5 0. 1 2 5 25 40 85 4 I A lot of product 
0.5 0. 1 2 5 25 3 5  1 50 4 I A lot of product 
0.5 0. 1 ' 5 25 50 I SO 4 1 No product 
0.5 0. 1 25 25 50 1 50 4 1 A lot of product 
0.5 0. 1 25 25 40 1 20 2 I Only traces of 
product 
0.5 0. 1 25 2 5  4 0  1 20 6 I A lot of product 
0.5 0. 1 25 25 35 1 20 4 1 Flow rate hardly 
controlled. 
0.5 0. l 25 25 50 1 20 4 J A lot of product 
0.5 0. 1 25 25 40 1 20 2 I A lot of product 
0.5 0. 1 25 2 5  40 1 20 4 1 A lot of product 
0.5 0. 1 25 25 40 1 20 4 0.5 A lot of product 
0.5 0. 1 25 25 40 1 1 0 4 I A lot of product 
0. 1 0 .375 2 5  4 0  1 1 0 4 I A lot of product 
0. 1 0 .375 25 40 1 1 0 6 1 Flow rate hardly 
control led. 
0.5 0. 1 25 25 40 1 1 0 4 I A lot of product 
0.5 0. 1 25 25 40 1 1 0 2 1 A lot of product 
0.5 0. 1 25 25 40 1 00 4 1 No product. 
0.5g 0. 1 25 25 40 1 50 1 1 *nozzJe size 
0. l 5 �m. A lot of 
product 
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Figu re 8. Photograph of the supercritical anti-solvent apparatus 
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Figu re 9.  Schemat ic  diagram of the SAS process 
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2.2 .2 .  C h a racteriza t ion  
2 .2 .2 . 1 .  canning Electron Micro copy ( S E M )  
The morphology and primary partic le ize of the neat polymers and neat drug , PYPlIbuprofen 
drug part ic le \ ere tudied u ing a canning electron micro cope eoScope JCM-5000 
uppl ied b Jeol Ltd . ,  Japan) .  Th ample were prepared by direct depo ition of the powder 
onto a carbon tap placed on the urface of an Aluminum tub.  Prior to SEM analysi the 
ample were coated \ i th gold for 4 minutes using a sputter coater after which they were fed 
into the micro cope. 
2 .2 .2 .2 .  Fourier Transform I nfrared pectroscopy ( FTIR) 
Tran mis ion infrared spech'a of a l l  samples were recorded at  room temperature using FT- I R  
( EXUS-470, Thermo icolet Corporation) spectrophotometer i n  the range o f  wavenumber 
from 4000 to 400 cm-I during 32 scans with 2 cm I resolution. Granules of each sample were 
mixed i n  a ratio  of 1 .0 wt% with KBr powder dried at 1 20°C for 24 hour . The mixture was 
mi l led to a fine powder and placed in a mold under the hydraul ic pressure to fom1 a KBr disc. 
The ample disc was mounted directly onto the sample holder and data for the pectra was 
col lected after scanning the background. 
2 .2 .2 .3 . Transmi ion E lectron M icroscopy (TEM) 
Transmission electron mIcroscopy (TE M )  is  a mIcroscopy technique whereby a beam of 
electrons is transmitted through an u l tra thin specimen containing the sample stained by Urinyl 
acetate stain .  By using a Phi l l ips e M ! 0 Transmi ttance Electron microscope, an electron beam 
was transmitted through a 200)lm mesh cupper grid coated with carbon membrane and traces 
of the sample in mi l l igrams were added to part ia l ly coat the grid. The samples were then 
contra ted by adding drops of 1 2% uranyl acetate stain for 3 minutes. The samples were 
injected into the TEM instrument, then as the electron beam passed through the specimen it 
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cau ed e citat Ion fol lo\ved b relaxation of the electrons of the ample and the image were 
formed from the interaction of the e lectron tran mi tted through the specimen . The image 
were th n magnified and focu ed onto a fluore cent creen. The image were printed on a l ayer 
of photographic fi lm and the fi lm were scanned into a computer. 
2 .2 .2 .4 .  DIfferential canning calorimetry ( D  ) 
D ifferential canning calorimetry or DSC i s  a thennoanalytical technique that measures the 
difference in the amount of heat required to increase the temperature of a sample and a 
reference, a a function of temperature. Both the sample and reference were maintained at 
nearly the am temperatur throughout the experiment. The temperature program for a DSC 
analy i wa de igned uch that the sample holder temperature increased l inearly as a function 
of t ime. 
Some amount of ample was transferred into a standard aluminum pan, weight was not 
important in thi tep s ince we were looking for the sample behavior. The sample holder was 
then co ered wi th aluminum cover. The a luminum capsule was transferred into the DSC 
in  trument programmed to run from 25°C to 600°C at 20°C/min heating rate and the 
e otherrnic or endothem1ic events related to crysta l l ization or melting were recorded. 
2 . 2 . 2 . 5 .  Thennogra imetric Analysi (TGA) 
TGA i s  a test perfonned on the neat drug neat polymer and the combinatIOn of the 
drug/polymer in the prepared micropaliic le that detennines the changes in weight or weight 
10 s in relation to changes in temperature .  Such analysis rel ies on a high degree of precision in 
three measurements :  weight, temperature, and temperature change. Analysis was carried out by 
raising the temperature of the sample gradual ly and plotting weight loss ( percentage) against 
the temperature . A few mi l l igrams of the sample were transferred into the aluminum pan and 
placed in the sample holder ( sensit ive electronic balance) in ide the TGA instrument. The 
in trument was programmed to run from 25°C to 600°C at a heating rate of 20°C/rn in .  After the 
data was obtained, curves were smoothed and points of inflection were detected. 
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2 .2 . 2 .6. Di olut ion Rate 
Di  olution rate of th drug \ as detem1ined by the paddle st irring method at 37  ± 0.5  °C with 
the tming peed of 1 00 rpm. Drug formulation equi alent to 1 00 mg of drug wa appl ied in 
500 ml of enz me-free imulated ga tric fluid (pH = 1 .4 ± 0 . 1 ) . Dissolution amples ( 1  ml) 
were col le ted at gi en t ime interval with the replacement of equal olume of temperature­
equi l ibrated media and fi l tered through 5 11m membrane fi l ters . These samples were di luted to 
1 0  ml with imulated ga tric fluid and the drug dis olved wa measured using an UV -Vis 
pectrophotometer at d ifferent t ime interval S ,  1 0, 1 5 , 20, 30, 45 and 60 minute . The trial 
were repeated wi th higher time durations of up to 1 80 minutes. 
36 
Chapter I I I  
Results an d d iscussion  
3 7  
III. Re u l t a n d  d i  cu s ion 
One of the mam objective of thi work wa to characterize the neat ibuprofen, neat 
poly\ inylp lTol idone and the prepared microcap ule . In order to achieve tbi objecti e, ix  
d ifferent characterization methods \ ere u d. Re ul ting image and graphs were analyzed in 
ord r to obtain th propert ie of the prepared micropart icle uch a their ize, shape order of 
the c ating la er and thennal propel1ie . 
3. 1 .  c a n n i n g  electron m icro copy ( S E M )  
E M  tud i a pnmary tep i n  obtain ing infoffi1ation about the surface area and morphology 
of the microcap ule . Magnification in a S E M  can be control led over a range of up to 6 orders 
of magnitude from about 1 0  to 500,000 times. F igures 1 0  to 1 6  show the vanou 
magnifications ranging between 5 to 200 microns. F igure 1 0 shows ibuprofen drug particles, 
which con i sted of i rregularly shaped crystal l ine morphology with sbarp edges, of around 1 00 
micron length . eat polyv inylpyrrol idone part ic les were regularly shaped spheres ranging 
from 1 0  to few hundred of micron diameter as shown in  F igure 1 1 . 
In general the temperature of the chamber in the SAS system ( 3 5°C- 50°C), has negl igible 
effect on the morphology. Thus the temperature was kept constant at 40°C. Also the 
concentration of the drug and polymer has been kept constant .  At a high pressure of 1 50 bar 
( Figure 1 2- 1 3  and 1 8) ,  microcapsule  were needle shape and the needles tended to agglomerate 
when the solution :C02 volume rat io  was increased ( Figure 1 2  1 4  1 5 , 1 6  and I 7) .  When the 
temperature and the solution :C02 volume ratios were kept con tant and the pressure was 
decreased, microcapsules had needle and star shapes at 1 20 bar ( Figure 1 4) .  These star shape 
micropartic les tended to agglomerate when the pressure was reduced and the microcapsules 
howed the hape of large chunks of stars at 90 bar (Figure 1 6) and 85 bar ( Figure 1 7) .  This i s  
due to the fact that the h igher the  pressure of the supercntical CO2 the higher i t s  densi ty and 
solvent power, which lead to better solub i l ity of drug and polymer in the supercli t ical CO2. 
Processing the polymer with SC CO2 does not leave residual organic solvent in the prepared 
drug/polymer micropart ic les s ince CO2 is a gas under ambient conditions. Once the process 
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wa complete and the tern pre ure wa reduced, CO2 left the ample. and eparated 
mlcropartlc le with a re lati e ly uniform particle ize di tribution were fom1ed. imilar 
conc lu Ion have been reported in  pre iou orks ( 73 ) . At a con tant pres ure ( J  50 bar) as the 
temperature wa decrea ed from 40°C to 35°C, the microcap ules tended to have the shape of 
agglomerated chunk ( Figure I ) . 
Figure 1 0 . SEM image of the neat ibuprofen 
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Figure 1 1 . SEM images for the neat polyvinylpynol idone 
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Figure 1 2 . SEM images for the PVP/ ibuprofen microcapsule prepared at 40°C 1 50 bar and 
4°'0 volume rat io 
4 1  
Fig u re 1 3 . SEM images for the PYPI ibuprofen microcapsule prepared at 40°C 1 50 bar and 
2° '0 volume rat io 
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Figu re 1 4 . SEM image for the PV P/ ibuprofen microcapsule prepared at 40°C, 1 20 bar and 
40 0 volume ratio 
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Figu re 1 5. SEM images for the PYP/ ibuprofen microcapsule prepared at 40°C 1 00 bar and 
4°"0 volume ratio 
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Figu re 1 6. SEM images for the PVP/ ibuprofen microcapsule prepared at 40°C, 90 bar and 4% 
volume rat io 
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Figu re 1 7. SEM images for the PVP/ ibuprofen microcapsule prepared at 40°C, 85 bar and 4% 
volume rat io 
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Figu re 1 8 . SEM images for the PVPI ibuprofen microcapsule prepared at 35°C, 1 50 bar and 
40 0 o lume ratio 
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Figu re 1 9 . SEM images for the PYP/ ibuprofen microcap ule prepared at 40°C, 1 1 0 bar and 
40 0 volume ratio 
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3.2 .  Fourier t ra n  fo rm i n fra red pectroscop ' ( FT I R) 
In  the l R  pectra the objecti e was to check the content of the microcap ules by tudying the 
I R  p ctra for the neat ibuprofen, the neat PVP pectrum and then comparing them with the 
prepared micropartic1e pectrum. eat polyvinylpyrrol idone pectrum had a broad band at 
3440 cm- I that a due to the tretching in the amine group -H ,  then a medium band at 2925 
cm- I mdicated the change of relati e ab orbencie of the band at 2925 cm- I (methylene groups 
of al iphatic ). Due to the carbonyl C=O group stretching there was the sharpest band at ] 662 
cm- I , and the re t of the noi e bands were due to the aromatic C-H bending motion . 
I n  the ca e of ibuprofen, FTI R  pectrum showed broad band between 2800-3 700 cm- I , whicb i 
due to tbe carboxyl ic acid O-H tretch ing motion, another band in  the range of 2500-3000 em- I 
wa due to O-H tretching motion, 0 erlapped wi th a broad smal l  band due to alcohol O-H 
group tretching motion, at 3200-3550  em- I . At 1 500- 1 700 cm· 1 there are two medium bands 
due to the aromatic C=C bond bending. Then there was a medium band at 600-900 cm- I which 
i due to the C-H bending and ring puckering. The C=O group of ibuprofen coated by PVP at 
1 727 cm- I was shifted to a higher wavenumber region, compared to the neat ibuprofen 
pectrum at 1 7 1 0  cm- I . This indicated the breakage of the ibuprofen-ibuprofen interaction , 
whicb are characteri t ics of the o l id form of this drug, once ibuprofen molecules were 
encap ulated into PVP u ing the SC CO:!. 
As for the spectrum of microcapsules in  ( Figure 20a-f) ,  al l  the samples of different pressures 
had the broad band due to the stretching of the - H  group, at 3440 cm-
I simi lar to the PVP 
spectra and the ibuprofen spectra . Another notable change in  the spech'a wa a decrease in the 
band to a value of 1 636 em- I , which was a shif to the lower wavenumber compared to the neat 
PVP at 1 652  cm- I . This shift was due to the H -bond between the C=O of the carbonyl group in  
the PVP with the O-H group of the ibuprofen . 
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nother mall  band appeared in  the microcap ule pectrum at 2920 cm-1 , due to the tretchino o 
motIOn of the carbox bc acid group, imi lar to the ibuprofen FTl R pectrum. Another indicator 
of th pre ence of the drug and the polymer in the microcapsule, appeared from the band at 
1 620 cm- I , when comparing thi band with the drug and the polymer spectrum, it wa 
concluded that thi band wa an overlapping between C=O tretching band at 1 662 cm- 1 from 
the P P pectrum, and the =C tretching band at 1 550 cm- 1 from the ibuprofen spectrum. 
doublet peak appeared between 1 550- 1 600 cm- 1 in the pectrum c ( l 00 bar), d (85 bar), e 
( 1 20 bar) and f (1 1 0  bar), when the volume ratio was ranging between 2-4%. I t  can be 
concluded that not a l l  the drug was encap ulated into PVP at lower pressures. The H -bond 
between ibuprofen and P P had an effect on the interaction between PVP and CO2. Evidence 
of thi  was hown from the p l i t  of the peak between 1 550- 1 600 cm- I in the FTI R  spectrum, 
corr ponding to the bending motion of CO2, which is a strong indication of CO2 interaction 
with the polymer. This i s imi lar to what ha been reported in earl ier works ( Kazarian et a I . ,  
1 996) (74) .  However thi spl i t t ing in  the bending motion tended to disappear once ibuprofen 
was encapsulated into PV P, indicating that in such a case the CO2 molecules did not interact 
wi th C=O group of PVP .  There is a lways competi t ive interaction of ibuprofen and CO2 
molecules with C=O group of PVP,  however ibuprofen is interacting more strongly with C=O 
group of PVP,  and thu expel the CO2 from the avai lable interaction basic s i tes of C=O 
group of PVP.  There were some CO2 that were t i  II interact ing with C=O groups of PVP and 
this was shown by the fact that orne d istortion of the bending motion of CO2 sti l l  existed after 
ibuprofen was encapsulated. 
On the other hand at the h igher pressure of 1 50 bar, which is presented at spectrum a ( Figure 
20),  there was only a s ingle peak at 1 600 cm- I due to the stretching motion of the C=O group in  
the PVP.  A medium band appeared at 1 330- 1 430 cm- I due to O-H bending in-plane motion. 
50 
40 00 3500 300 0 2 50 0  2 000 1 5 00 1 0 00 50 0 
Figure 20.  FTIR spectra for the neat polyvinylpyrrol idone, neat ibuprofen drug, (a)  PYPI 
ibuprofen microcapsule prepared at 1 50 bar and 40°C, (b) PVPI ibuprofen microcapsule 
prepared at 40°C, 1 20 bar 4% volume rat io, ( c )  PV PI ibuprofen microcapsule prepared at 40°C 
and 1 00 bar, ( d) PVPI ibuprofen microcapsule prepared at 40°C and 85 bar, (e )  PVPI ibuprofen 
microcapsule  prepared at 40°C, 1 20 bar 2% volume ratio, ( f) PYPI ibuprofen microcapsule 
prepared at 1 1 0 bar and 40°C 
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3 .3 .  Tran m i  ion E l ec tro n  M icro cop ( T E M )  
The tran mi ion e lectron micro cop (TEM ) u e electron instead of l ight a a l ight ource, 
\ hlch make it appl icable for variou material unl imited to a certain wavelength a in the l ight 
micro cope, and it ha a higher re olution a " e l l .  
TEM micrograph can reach to  the  order of a few angstroms ( 1 0- 1 0 m) (atomic Ie e l s ) .  These 
high magn ification of TEM made it a aluable tool in both medical biological and materia ls  
re earch. 
TEM image of the neat polyvinylpyrrol idone showed needle shape particle with a dark color 
a hown in  F igure 2 1 .  The s ize of the polymer part ic les was less than 1 micron, whereas the 
ibuprofen drug showed a darker color in contrast to the polymer as depicted in Figure 22. The 
TEM image of the part ic les ize was ranging between 1 0  microns and 1 00 microns of star 
hape part ic le . 
I n  the case of the po\yvinylpyrrol idone/ibuprofen microparticles, which were prepared at 35°C, 
1 20 bar, 4°10 drug-polymer solution to CO? volume ratio and 1 mllmin flow rate, the TEM 
graphs di played a uniform morphology of pherical shaped particles with two layers, as an 
indication of the drug l ayer and the polymer layer. The micropart icle had the size of 0. 1 
micrometer diameter as shown in  F igure 23 .  When temperature was increased by 1 5  degrees at 
50°C, TEM image ( Figure 24) showed the ibuprofen! Polyvinylpyrrol idone microparticles of 
s imilar s ize to those observed in Figure 22 but the layers of the polymer and the drug were 
clearer. The l ighter colour of the outer layer was an indicator of the polyvinylpyrrol idone layer 
and the darker colour of the i nner layer was an indicator of the ibuprofen drug. Reducing the 
pressure in the preparation of the drug polymer microcapsule reduced the number of produced 
microspheres. 
Stain ing the samples wi th uranyl acetate stain, enhanced the contrast of the resul ting TEM 
image, and protected the samples from buming under the high energy radiation of the electron 
beam. 
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Figu re 2 1 .  Transmi sion electron micrograph of the neat polyvinylpyrrol idone 
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Figu re 22.  Transmission electron micrograph of the neat ibuprofen 
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Figu re 23 .  Transmission electron micrograph of the encapsulated PVP and ibuprofen drug at 
3 5°C, l 20bar, 4% volume rat io  and 1 mllmin flow rate 
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Figu re 24 .  Transmission electron micrograph of the encap ulated PVP and ibuprofen drug at 
50°C, 1 20 bar, 4°� volume rat io  and 1 mlfmin flow rate 
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Figu re 25. Tran mi  s ion electron micrograph of the encapsulated PVP and ibuprofen drug at 
'+O°c, 1 1 0 bar, 2° 0 volume ratio and 1 mllmin  flow rate 
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3.4 Differen t i a l  c a n n i n g  ca l ori metry ( D  C) 
o re ul t  of P P polymer ( Figure 26a) howed the gla transition temperature, which 
appeared a an endothelmic peak at 1 75°C of the recorded D C signal. This \ a due to the 
ample undergoing a chang in the heat capacity, a the temperature of an amorphou ol id wa 
mcr a ed with no fonnal pha e chang . The cross-l inking of the PYP molecule that may occur 
in the curing ( hardening) proce of the polymer is exothermic, resul ted with a positive peak at 
1 50°C in the D C curve . Thi peak usua l ly appear oon after the gla tran it ion temperature. 
A negative peak wa ob er ed at 450°C due to melt ing of the PYP polymer. 
D C results for the ibuprofen drug hown in ( Figure 26b), started with a sharp endothermic 
peak cau ed by the loss of moi ture content in  the drug due to the constant heating. A 
fol lowing exothem1ic peak appeared at 1 00°C, due to the exothem1ic crystal l ization process. I t  
i de i rable to proce s the drug at  temperatures below tho e at which crystal l ization can occur 
if it hould be del i ered in amorphous phase. 
DSC re ult of the PVPlibuprofen microcapsules ( Figure 26c) showed the first endothennic 
peak due to the gla trans i t ion of the polymer. This peak also corresponds to the moisture los 
in the ibuprofen drug. Neat PYP had a nalTower and a sharper peak in comparison with the 
conditioned PYP/ibuprofen micropart icles .  
I n  the DSC results, the endothermic peak corresponding to the net ibuprofen was also observed 
for the prepared PYPlibuprofen micropart icles using SC CO2 indicating an incomplete 
inc lusion of the drug in PYP .  This agreed with the TEM results when the ibuprofen was the 
shel l and the PYP was the core of the micropart ic les .  The exothermic crysta l l ization process 
occurred at 300°C, which was l ightly sh ifted from the crystal l ization peak of the drug and the 
polymer. 
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Figu re 26. Different I al anning calorimetry curv (a )  for the neat P p,  (b )neat ibuprofen and 
( c )  microcap ule prepared b upercri t ical CO:! technique at 40°C, ] 50 bar, 4°'0 olume ratio  
and ] m l  min flow rate. 
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3.5 Therm ogravi met ric a n a l ' i (TCA) 
The TG diagram obtained for the neat ibuprofen ( Figure 27a)  howed a mal l decrease at 
around 1 00°e, due to the 10 of moi ture and a more ignificant 10 s at about 300°C. The PVP 
pol mer al 0 lost i t  w ight ( about 1 2%) at around l oooe ( Figure 27b) .  Howe er, the major 
weIght los ( about 70 0 0) in  the polymer occurred at around 400 °C. The TGA diagram of the 
microparticle ( Figure 27c) howed c learly the different regions of weight loss associated with 
the drug and the polymer. This was clear where the capsule lost 22 .4% of its weight at 300oe,  
v; hich i due to drug weight loss and 24% loss at 4000e due to PVP weight los . This indicates 
that the microcap ule contain two different materials namely the ibuprofen and the PYP .  And 
it i a confirmation of the FTl R  results, which showed the different peaks of the PYP and the 
ibuprofen in the I R  spectrum of the prepared microcapsule . 
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Figure 27.  Thennogravimetric analysi for the ( a) neat ibuprofen, (b )  the neat 
polyvinylpyrro l idone and ( c )  the microcapsule prepared by supercri tical CO:! techn ique at 
40°C, 1 50 bar 40/0 olume ratio  and 1 m1lmin  flow rate 
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3.6. 0i o lu t ion  rate t u d  
Oi  olution profil  f ample prepared a t  d ifferent treatment pre sure and temperatures were 
detem1ined, in order to ee the effect of SC treatment condition on ibuprofen di olution in  
imulated ga tric fluid .  Re ult of the di o lution rate for d ifferent samples are hown in  Figure 
2 . The highe t absorbance of ibuprofem in the UV -Vi ible spectrophotometer was at 265 nm. 
PVP, ibuprofen micropart ic le prepared at 35°C , 1 20 bar, 4% volume ratio and 1 mllmin 
howed the h ighe t di olution rate ( Figure 28) ,  where the drug in the beginn ing dissolved 
rapidl in the simulated gastric fluid, e pecial ly before 60 minutes from the start of the 
di olut ion e 'periment, however, after 60 minutes the drug concentration dropped to around 50 
fig m! .  Thi i s  imi lar to what other have concluded in the l iterature . Ibuprofen that is  inside 
the polymer matrice ha been shown to be amorphou and easier to be released than i f  the 
drug and polymer were imple mixtures where they exist in their crysta l l ine forms ( 75 ) . On the 
other hand the neat ibuprofen had lower d i  olution rate than the encapsulated ibuprofen into 
PVP, u ing upercrit ical C02 at 35°C, 1 20 bar and 4% olume rat io.  PVP/ ibuprofen 
microcapsule howed more control led release of the drug from the microparticles when they 
were prepared at h igher temperate (40°C and 50°C) .  In the e samples,  the concentrations of 
ibuprofen in  the imulated gastric fluid were about 1 5  fig/ml ,  and remained constant indicating 
a contro l led release of the drug from the micropart ic les. This control led release of the drug is  
becau e in  these samples the polymer coated the drug, confirming the TEM images of these 
amples.  
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Figu re 28.  Dissolut ion rate for (+) Pure Ibuprofen, ( A )  PVPlibuprofen microcapSUles 
prepared at  3SoC, 1 20 bar, 4% olume ratio, 1 mllmin, ( _ )  PVPlibuprofen microcapSUles 
prepared at 40°C, 1 1 0 bar, 4% volume rat io, 1 mllmin flow rate, ( x) PYP/ibuprofen 
microcapSUles prepared at SO°C, 1 20 bar, 4% volume ratio,  1 mllmin flow rate. 
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C h apter I V. ConcJu  ion  
From the EM re ult i t  can be concluded that the higher pre ure (e .g .  1 20 or  1 50 bar) gave 
mor eparated microparticle and mai ler part ic le izes ( e .g. mall chunks of 1 0  micron ) .  
M lcropart ic le that were pr pared at lower pre ure ( e .g. 90 or 5 bar) were bigger i n  ize 
howing agglomerated chunk . Thi might have been caused by the pre ence of the organic 
olvent in the ample wh i le  at the higher pre sure, supercri tical CO2 could remove the organic 
olvent due to the higher olub i l i ty of the olvent in  supercritical CO2 at the higher pre sure . .  
Thi w a  confiml d from the doublet peak of the FTI R  te t for the microcapsules, which were 
prepared at lower pre ure ( i .e .  85 bar, 1 00 bar). 
imi larly. the higher the flov rate, the higher the presence of the organic olvent ( ethanol)  in 
the prepared drug-polymer micropart icles .  SEM re ults howed the agglomeration of the 
micropart icles prepared at h igher flow rates. Shorter contact t ime between the drug-polymer 
olut ion and upercri t ical CO2 at higher flow rates prevents the supercritical CO2 from 
removing a l l  the organic solvent from the drug-polymer solution. Therefore, lower flow rates 
( l  mllmin)  and thus h igher contact t imes resulted in well  separated micrparticle . 
FTI R result  clearly showed the presence of the PVP polymer and the ibuprofen in the drug­
polymer micropart ic le samples, which wa the first goal of the work . TGA resul ts confirmed 
the fact that both PVP and ibuprofen molecules were present in the prepared microcapsule 
ample . TEM results confirmed that PVP polymerlibuprofen micropart ic les were prepared and 
the ibuprofen wa encapsulated into the PVP polymer. TEM results a l so showed that the 
prepared microcap u les were of smal l  s izes that could reach 0 . 1 microns in diameter. 
Final ly,  the dissolution rate of the ibuprofen from tbe drug-polymer micropart icles prepared at 
the low temperature of 3 SoC showed a s l ight increase in comparision with the neat ibuprofen 
drug. indicating an enhancement of the solub i l i ty of the ibuprofen drug in the gastric fluid after 
the encapsu lation in to PVP polymer. On the other hand, a more control led release was noticed 
from the microparticles which were prepared at h igh temperatures (40°C and 50°C), which 
might be due to the thicker polymer l ayer covering the drug at the e temperatures. 
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